Common Contracts

EX-10.1 2 d708097dex101.htm EX-10.1

Co-Promotion Agreement • May 5th, 2020 • New York

• Contract Type
  Co-Promotion Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934.

CO-PROMOTION AGREEMENT by and among AMARIN PHARMACEUTICALS IRELAND LIMITED, AMARIN PHARMA, INC. and KOWA PHARMACEUTICALS AMERICA, INC. MARCH 31, 2014

Co-Promotion Agreement • May 9th, 2014 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York

• Contract Type
  Co-Promotion Agreement
• Filed
  May 9th, 2014
• Company
  Amarin Corp Plc\uk
• Industry
  Pharmaceutical preparations
• Jurisdiction
  New York

This Co-Promotion Agreement (this “Agreement”) is entered into as of March 31, 2014 (the “Effective Date”) by and among Amarin Pharmaceuticals Ireland Limited, a company incorporated under the laws of Ireland (registered number 408912) with offices at 2 Pembroke House Upper Pembroke Street 28-32, Dublin 2, Ireland (“Amarin Ireland”), and Amarin Pharma, Inc., a Delaware corporation with offices at 1430 Route 206 North, Suite 101, Bedminster, NJ 07921 (“Amarin Pharma”, and collectively with Amarin Ireland, “Amarin”), on the one hand, and Kowa Pharmaceuticals America, Inc., a Delaware corporation with offices at 530 Industrial Park Blvd, Montgomery, AL 36117 (“Kowa”), on the other hand.